Search

Your search keyword '"Karetnikova VN"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Karetnikova VN" Remove constraint Author: "Karetnikova VN"
43 results on '"Karetnikova VN"'

Search Results

1. Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percu-taneous Coronary Intervention for Type 2 Diabetes Mellitus.

2. Expression of adipocytokines in heart fat depots depending on the degree of coronary artery atherosclerosis in patients with coronary artery disease.

3. The relationship of the epicardial fat and adipo-fibrokines in myocardial infarction.

4. [Dynamics of Parameters of Transmitral Blood Flow and Markers of Myocardial Fibrosis in Patients with Myocardial Infarction].

5. [Effect of empagliflosin on renal filtration in patients with coronary heart disease undergoing percutaneous coronary intervention].

6. [Adiponectin gene expression in local fat depots in patients with coronary heart disease depending on the degree of coronary lesion].

7. [Polyvascular disease in patients with myocardial infarction and chronic kidney disease].

8. The marker of adverse prognosis 1.5-anhydroglucitol in patients with coronary heart disease in the long-term period after planned myocardial revascularization.

9. [Expression of gene and content of adiponectin in fatty tissue in patients with ischemic heart disease].

10. Influence of visceral obesity on the secretion of adipokines with epicardial adipocytes in patients with coronary heart disease.

11. [The association of biological markers with echocardiographic indices in patients with myocardial infarction with ST segment elevation and preserved left ventricular ejection fraction].

12. Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with Coronary Heart Disease.

13. Serum neutrophil gelatinase-associated lipocalin has an advantage over serum cystatin C and glomerular filtration rate in prediction of adverse cardiovascular outcome in patients with ST-segment elevation myocardial infarction.

14. [Myocardial fibrosis: Current aspects of the problem].

15. [Clinical and Prognostic Value of Serum Neutrophil Gelatinase-Associated Lipocalin in Patients With ST-Segment Elevation Myocardial Infarction].

16. [Relationship Between Blood Serum Galectin and Renal Dysfunction in ST Elevation Myocardial Infarction].

17. [The Study of Associations of Polymorphisms of Candidate Gene of Cardiovascular Diseases With Reduction of Glomerular Filtration Rate in Patients With ST Segment Elevation Myocardial Infarction].

18. [The possibility of application of stimulant growth factor (ST2) for verifying postinfarction remodeling of myocardium.]

19. [The role of chronic kidney disease in assessing the risk of the poor course of hospital ST-segment elevation myocardial infarction].

20. [Renal function estimation formulas in predicting long-term cardiovascular outcomes in patients with myocardial infarction concurrent with diabetes mellitus].

21. [Diagnostic value of the stimulating growth factor ST2 during hospitalization for myocardial infarction].

22. [The Impact of Renal Dysfunction on Outcomes of In-Hospital and Remote Periods in Patients With ST-Elevation Myocardial Infarction Combined With Type 2 Diabetes Mellitus].

23. [Renal dysfunction in patients with myocardial infarction concurrent with type 2 diabetes mellitus].

24. [Impact of chronic obstructive pulmonary disease on one-year prognosis in patients with ST-segment elevation myocardial infarction].

25. [The Impact of Renal Dysfunction on Outcomes of In-Hospital and Remote Periods in Patients With ST-Elevation Myocardial Infarction Combined With Type 2 Diabetes Mellitus].

26. [NON-CORONARY ATHEROSCLEROSIS PROGRESSION AFTER MYOCARDIAL INFARCTION IN PATIENTS OF DIFFERENT AGE GROUPS].

27. [THE SYSTEM OF SOLUBLE LEPTIN RECEPTORS AND PROINFLAMMATORY FACTORS IN MYOCARDIAL INFARCTION].

28. [Efficacy of percutaneous coronary intervention in patients with ST elevation myocardial infarction and impaired glucose tolerance or diabetes mellitus].

29. [Biochemical characteristics associated with diabetes mellitus one year after myocardial infarction].

30. [New-onset chronic obstructive pulmonary disease and its clinical significance in patients with ST-segment elevation myocardial infarction].

31. [The markers of lipid transport system of blood and annual prognosis of cardiac infarction].

32. [Risk factors of contrast-induced nephropathy in patients with myocardial infarction].

33. [Role of kidney injury molecule-1 (KIM-1) for inhospital event risk assessment after coronary artery bypass surgery].

34. [The detection of leptin and metabolic markers of insulin resistance in patients with myocardial infarction].

35. [Multifocal atherosclerosis as a factor of unfavorable prognosis in patients with ST elevation myocardial infarction and type 2 diabetes mellitus].

36. [The incidence and significance of chronic obstructive pulmonary disease in patients with myocardial infarction and elevated st segment].

37. [Lipid, adipokine and ghrelin concentrations in myocardial infarction patients with insulin resistance].

38. [Role of renal dysfunction and multifocal atherosclerosis in assessment of prognosis of patients presenting with ST-elevation acute coronary syndrome].

39. [Level of glycemia as a marker of prognosis in patients with myocardial infarction with ST segment elevation].

40. [The role of markers of inflammation in assessment of prognosis in patients with ST-elevation myocardial infarction combined with disturbances of carbohydrate metabolism].

41. [Prognostic value of various markers of inflammation in ST-elevation myocardial infarction].

42. [Effect of thrombolytic therapy on parameters of endothelial function in patients with myocardial infarction].

43. [Clinical and prognostic significance of the degree of delayed ventricular function and vegetative regulation of cardiac rhythm in myocardial infarction patients].

Catalog

Books, media, physical & digital resources